Literature DB >> 33652938

Clinical Relevance of [18F]Florbetaben and [18F]FDG PET/CT Imaging on the Management of Patients with Dementia.

Damiano Librizzi1, Nicole Cabanel2,3, Maxim Zavorotnyy2,4,3, Elisabeth Riehl1, Tilo Kircher2,3, Markus Luster1, Behrooz Hooshyar Yousefi1.   

Abstract

PET of β-Amyloid plaques (Aβ) using [18F]florbetaben ([18F]FBB) and [18F]fluorodeoxyglucose ([18F]FDG) increasingly aid clinicians in early diagnosis of dementia, including Alzheimer's disease (AD), frontotemporal disease, dementia with Lewy bodies, and vascular dementia. The aim of this retrospective analysis was to evaluate clinical relevance of [18F]FBB, [18F]FDG PET and complimentary CSF measurements in patients with suspected dementia. In this study, 40 patients with clinically suspected or history of dementia underwent (1) measurement of Aβ peptides, total tau, and p-tau protein levels in the cerebrospinal fluid (CSF) compared with healthy controls (HC); (2) clinical and neuropsychological assessment, which included Consortium to Establish a Registry for Alzheimer's Disease neuropsychological assessment battery (CERAD-NAB); (3) [18F]FBB and [18F]FDG PET imaging within an average of 3 weeks. The subjects were within 15 days stratified using PET, CSF measurements as HC, mild cognitive impaired (MCI) and dementia including Alzheimer´s disease. The predictive dementia-related cognitive decline values were supporting the measurements. PET images were evaluated visually and quantitatively using standard uptake value ratios (SUVR). Twenty-one (52.5%) subjects were amyloid-positive (Aβ+), with a median neocortical SUVR of 1.80 for AD versus 1.20 relative to the respective 19 (47.5 %) amyloid-negative (Aβ-) subjects. Moreover, the [18F]FDG and [18F]FBB confirmed within a sub-group of 10 patients a good complimentary role by correlation between amyloid pathology and brain glucose metabolism in 8 out of 10 subjects. The results suggest the clinical relevance for [18F]FBB combined with [18F]FDG PET retention and CFS measurements serving the management of our patients with dementia. Therefore, [18F]FBB combined with [18F]FDG PET is a helpful tool for differential diagnosis, and supports the patients' management as well as treatment.

Entities:  

Keywords:  Alzheimer’s disease; MCI; Positron Emission Tomography (PET); dementia; diagnostic imaging; neurofibrillary tangles; patient management; β-amyloid plaques

Mesh:

Substances:

Year:  2021        PMID: 33652938      PMCID: PMC7956266          DOI: 10.3390/molecules26051282

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  36 in total

1.  [German Society of Nuclear Medicine procedure guideline on beta-amyloid brain PET imaging].

Authors:  Henryk Barthel; Philipp T Meyer; Alexander Drzezga; Peter Bartenstein; Henning Boecker; Peter Brust; Ralph Buchert; Heinz H Coenen; Christian la Fougère; Gerhard Gründer; Frank Grünwald; Bernd J Krause; Torsten Kuwert; Matthias Schreckenberger; Klaus Tatsch; Karl-Josef Langen; Osama Sabri
Journal:  Nuklearmedizin       Date:  2016-04-15       Impact factor: 1.379

2.  F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain.

Authors:  Wei Zhang; Shunichi Oya; Mei-Ping Kung; Catherine Hou; Donna L Maier; Hank F Kung
Journal:  Nucl Med Biol       Date:  2005-11       Impact factor: 2.408

Review 3.  Fluorine-18 labelled building blocks for PET tracer synthesis.

Authors:  Dion van der Born; Anna Pees; Alex J Poot; Romano V A Orru; Albert D Windhorst; Danielle J Vugts
Journal:  Chem Soc Rev       Date:  2017-07-31       Impact factor: 54.564

4.  Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients.

Authors:  Henrik Zetterberg; Kristian Tullhög; Oskar Hansson; Lennart Minthon; Elisabet Londos; Kaj Blennow
Journal:  Eur Neurol       Date:  2010-06-03       Impact factor: 1.710

5.  Prefrontal hypometabolism in Alzheimer disease is related to longitudinal amyloid accumulation in remote brain regions.

Authors:  Elisabeth Klupp; Timo Grimmer; Masoud Tahmasian; Christian Sorg; Igor Yakushev; Behrooz H Yousefi; Alexander Drzezga; Stefan Förster
Journal:  J Nucl Med       Date:  2015-02-12       Impact factor: 10.057

6.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease.

Authors:  J C Morris; A Heyman; R C Mohs; J P Hughes; G van Belle; G Fillenbaum; E D Mellits; C Clark
Journal:  Neurology       Date:  1989-09       Impact factor: 9.910

7.  Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.

Authors:  Christopher C Rowe; Uwe Ackerman; William Browne; Rachel Mulligan; Kerryn L Pike; Graeme O'Keefe; Henry Tochon-Danguy; Gordon Chan; Salvatore U Berlangieri; Gareth Jones; Kerryn L Dickinson-Rowe; Hank P Kung; Wei Zhang; Mei Ping Kung; Daniel Skovronsky; Thomas Dyrks; Gerhard Holl; Sabine Krause; Matthias Friebe; Lutz Lehman; Stefanie Lindemann; Ludger M Dinkelborg; Colin L Masters; Victor L Villemagne
Journal:  Lancet Neurol       Date:  2008-01-10       Impact factor: 44.182

8.  Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease.

Authors:  Matteo Cotta Ramusino; Valentina Garibotto; Ruggero Bacchin; Daniele Altomare; Alessandra Dodich; Frederic Assal; Aline Mendes; Alfredo Costa; Michele Tinazzi; Silvia D Morbelli; Matteo Bauckneht; Agnese Picco; Massimo E Dottorini; Cristina Tranfaglia; Lucia Farotti; Nicola Salvadori; Davide Moretti; Giordano Savelli; Anna Tarallo; Flavio Nobili; Maura Parapini; Carlo Cavaliere; Elena Salvatore; Marco Salvatore; Marina Boccardi; Giovanni B Frisoni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-06       Impact factor: 9.236

Review 9.  Shared mechanisms of neurodegeneration in Alzheimer's disease and Parkinson's disease.

Authors:  Anmu Xie; Jing Gao; Lin Xu; Dongmei Meng
Journal:  Biomed Res Int       Date:  2014-05-12       Impact factor: 3.411

10.  FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice.

Authors:  Behrooz H Yousefi; Boris von Reutern; Daniela Scherübl; André Manook; Markus Schwaiger; Timo Grimmer; Gjermund Henriksen; Stefan Förster; Alexander Drzezga; Hans-Jürgen Wester
Journal:  EJNMMI Res       Date:  2015-03-28       Impact factor: 3.138

View more
  3 in total

1.  Quantitative Brain Positron Emission Tomography in Female 5XFAD Alzheimer Mice: Pathological Features and Sex-Specific Alterations.

Authors:  Caroline Bouter; Caroline Irwin; Timon N Franke; Nicola Beindorff; Yvonne Bouter
Journal:  Front Med (Lausanne)       Date:  2021-11-26

2.  A Systematic Review of the Impact of Physical Exercise-Induced Increased Resting Cerebral Blood Flow on Cognitive Functions.

Authors:  Maria B Renke; Anna B Marcinkowska; Sylwester Kujach; Paweł J Winklewski
Journal:  Front Aging Neurosci       Date:  2022-02-14       Impact factor: 5.750

3.  Circulating exo-miR-154-5p regulates vascular dementia through endothelial progenitor cell-mediated angiogenesis.

Authors:  Xue Han; Li Zhou; Yu Tu; Jiajia Wei; Jiajia Zhang; Guojun Jiang; Qiaojuan Shi; Huazhong Ying
Journal:  Front Cell Neurosci       Date:  2022-07-29       Impact factor: 6.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.